Header Logo

Connection

Lynn Morris to Double-Blind Method

This is a "connection" page, showing publications Lynn Morris has written about Double-Blind Method.
Connection Strength

0,217
  1. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med. 2021 03 18; 384(11):1003-1014.
    View in: PubMed
    Score: 0,043
  2. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Med. 2020 05; 17(5):e1003117.
    View in: PubMed
    Score: 0,041
  3. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Med. 2020 02; 17(2):e1003038.
    View in: PubMed
    Score: 0,040
  4. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018 11; 18(11):1241-1250.
    View in: PubMed
    Score: 0,037
  5. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018 07; 5(7):e366-e378.
    View in: PubMed
    Score: 0,036
  6. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010 Sep 03; 329(5996):1168-74.
    View in: PubMed
    Score: 0,021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.